Brown Rudnick represented Hallux, Inc. in a $7.1 million Series A financing with Deerfield Management as the lead investor. Hallux is an investigational-stage pharmaceutical company focused on developing a new dosage form and route of administration for treating onychomycosis. The Brown Rudnick team was led by Corporate Partner Rob Funsten and Corporate Associates Michael Cohen, Sarah Wilk and Mary Ambacher. Support for the transaction was provided by Tax Partner Vince Guglielmotti and Associate Stephanie Bollheimer.

To learn more about this deal, please read the following press release: